Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets.
Lead Product(s): Undisclosed
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration January 23, 2023
Details:
The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $110.0 million Upfront Cash: $20.0 million
Deal Type: Expanded Collaboration September 20, 2022
Details:
The new research agreement and investment will support the development of additional disease models and the creation of high-resolution models, spanning across a number of therapeutic areas.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration September 20, 2022
Details:
This collaboration might help identify which type of tumor the drug will be most effective for, and has the potential to save the lives of millions who suffer from cancer.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 20, 2021